Bharat Serums and Vaccines

What Bharat Serums and Vaccines does

Bharat Serums and Vaccines Limited (BSV) is an India-based biopharmaceutical company founded in 1971 by Dr. Vinod Daftary and headquartered in Mumbai, operating across four therapeutic areas: Women's Health (infertility, Rh incompatibility, endometriosis, PCOS), Assisted Reproductive Therapy (recombinant FSH and HCG for IVF/IUI), Critical Care (antifungals, antibiotics, volume expanders, burn treatments), and Emergency Medicine (anti-snake venom serum, anti-rabies serum). The company pioneered the world's 1st marketed recombinant Anti Rh(o)-D immunoglobulin (Trinbelimab) and holds first-in-India positions across biosimilar rFSH, monoclonal tetanus, anti-thymocyte globulin, and NDDS-based Amphotericin B emulsion formulations, supported by 15+ product patents globally.

BSV operates an integrated biopharmaceutical platform with manufacturing facilities in Ambernath, India (5 injectable lines, 2 API lines) and Baesweiler, Germany (US FDA-approved facility, 120+ batches per annum), regulated under US FDA, EU GMP, ANVISA, WHO GMP, and PIC/s certifications. The company distributes products across 70+ countries through 17-country field sales teams, a 300-member global distribution network, and wholly-owned subsidiaries in the Philippines, Malaysia, and Germany. R&D is anchored by 60-100+ scientists in Mumbai working on monoclonal antibodies, biosimilars, equine biologicals, and novel drug delivery systems.

In October 2024, Mankind Pharma Limited acquired 100% of BSV for INR 13,768 crore (~$1.6 billion), making BSV a wholly-owned subsidiary within the Mankind Group while maintaining distinct brand and operational identity. BSV's revenue model is anchored in pharmaceutical formulation sales across its four therapy verticals, with pricing subject to NPPA ceiling regulations in India and discretionary pricing across international markets. The company employs 1,001-5,000 people, serves hospitals, fertility clinics, IVF centers, and government immunization programs as primary customers, and operates supporting digital platforms including BSVwithU (HCP knowledge hub) and StartYourJoy (IVF financing).

Name

Bharat Serums and Vaccines

Legal name

Bharat Serums and Vaccines Limited

Website

https://bsvgroup.com

Company type

Private

Founded year

1971

Operating status

Acquired

Headcount range

1,001–5,000 employees

Short description

BSV is an India-based biopharmaceutical company developing women's health, fertility, critical care, and emergency medicine products across 70+ countries. A wholly-owned subsidiary of Mankind Pharma since October 2024, BSV operates US FDA-approved manufacturing in India and Germany and pioneered the world's 1st recombinant Anti-D immunoglobulin.

Ownership category

akta.pro rank

Product category

Specialty Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM), Vaccine Programs & Tendering (Government/NGO, Eradication Campaigns) (HLAMAKAO)

Keywords

• Biopharmaceutical products
• Women's health therapeutics
• Assisted reproductive therapy
• Critical care medicines
• Emergency medicine treatments

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Formulation Sales: Sale of biopharmaceutical products across Women's Health, Assisted Reproductive Therapy, Critical Care, and Emergency Medicine segments globally through direct sales teams and distribution networks
2. Specialty Portfolio Integration: Mankind Pharma acquired BSV for ₹13,630 crore in 2024, integrating BSV's specialty portfolio including women's health and fertility drugs, contributing to Mankind's chronic therapy growth

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

BSV develops, manufactures, and commercializes specialty biopharmaceutical products including monoclonal antibodies, biosimilar gonadotropins, equine biologicals, recombinant proteins, and novel drug delivery system (NDDS) formulations. Its portfolio spans four therapeutic areas — Women's Health (fertility, Rh incompatibility, endometriosis), Assisted Reproductive Technology (IVF/IUI hormones), Critical Care (antifungals, anticoagulant reversal, burns), and Emergency Medicine (anti-snake venom, anti-rabies). Products are manufactured at US FDA/EU GMP-certified facilities in Ambernath (India) and Baesweiler (Germany) and distributed across 70+ countries.

Product overview

BSV is a biopharmaceutical company with a diversified portfolio of biological, biotech, and pharmaceutical products organized across four core therapeutic areas: Women's Health (fertility, Rh incompatibility, endometriosis, pregnancy care), Assisted Reproductive Technology (IVF/IUI support hormones and procedures), Critical Care (antifungals, antibiotics, volume expanders, burn treatments, anticoagulant reversal agents), and Emergency Medicine (snake bite, dog bite, rabies). The company pioneered the World's 1st recombinant Anti Rh(o)-D Immunoglobulin (Trinbelimab) and offers a comprehensive range of biosimilar fertility hormones including recombinant FSH and HCG. Critical care portfolio includes Amphotericin B, 4F-PCC, and Novel Drug Delivery System formulations. Emergency medicine covers anti-snake venom serum, anti-rabies serum, and anti-thymocyte globulin. BSV operates patient support platforms including BSVwithU for healthcare professional education and StartYourJoy for IVF financial assistance.

Differentiator

Problem solved

Functional benefit

Brands

• Trinbelimab: World's 1st recombinant Anti Rh(o)-D Immunoglobulin for prevention of Rh isoimmunization in pregnant women
• ASVS (Anti-Snake Venom Serum)
• AntiD
• StartYourJoy
• BSVwithU
• HumogHD
• rHCOG

Products and services

• Trinbelimab (Recombinant Anti Rh(o)-D Immunoglobulin) World's 1st marketed recombinant Anti Rh(o)-D Immunoglobulin used in prevention of Rh isoimmunization by preventing Rh-negative mothers from forming antibodies towards Rh-positive fetus red blood cells during childbirth, abortion, or sensitizing events. Helps prevent hemolytic disease in newborns (HDN). Targeted at pregnant Rh-negative women and obstetricians.
• Anti-Snake Venom Serum (ASVS) Polyvalent Anti-Snake Venom Serum prepared from purified serum of hyperimmunized horses, targeting India's Big Four venomous snakes: Indian Cobra, Russell's Viper, Common Krait, and Saw-scaled Viper. Used for treating life-threatening venomous snakebites.
• Anti-Rabies Serum Equine-derived anti-rabies antiserum used for post-exposure prophylaxis following potential rabies exposure from animal bites. First-in-India biological product.
• Anti-Thymocyte Globulin Equine-derived immunoglobulin used for immunosuppression in transplant patients and treatment of aplastic anemia. BSV is the sole manufacturer in India.
• HumogHD (Recombinant FSH) Recombinant Follicle-Stimulating Hormone (r-FSH) biosimilar for ovarian stimulation in fertility treatments. Pen injection presentation available in 300, 450, 900 & 1200 IU strengths.
• rHCOG (Recombinant Human Chorionic Gonadotropin) Recombinant human chorionic gonadotropin hormone used in ART procedures in conjunction with FSH to trigger final follicular maturation. Available at 6500 IU in prefilled syringe.
• Folliculin (Urinary HCG) Urinary-derived human chorionic gonadotropin for fertility treatments and luteal support.
• Amphonex (Amphotericin B Emulsion) Amphotericin B formulation using a Novel Drug Delivery System for treatment of severe systemic fungal infections. Critical care product addressing high mortality rate invasive fungal infections.
• Octaplex (4-Factor Prothrombin Complex Concentrate) Plasma-derived, virally inactivated Human 4-Factor Prothrombin Complex Concentrate containing coagulation factors II, VII, IX, and X. Used for reversal of oral anticoagulant agents (VKAs) and treatment of bleeding in vitamin K-dependent coagulation factor deficiencies.
• Luprodex (Leuprolide Acetate) GNRH agonist delivered via novel drug delivery system for the treatment of endometriosis, precocious puberty, and fertility protocols.
• NexoBrid Enzymatic debridement agent (concentrate of proteolytic enzymes enriched in bromelain) for topical treatment of deep partial and full-thickness thermal burns that can treat patients within hours without harming viable tissue. Distributed in India under exclusive agreement with MediWound.
• AntiD Specialized immunoglobulin product line for Rh-negative mothers to prevent sensitization. Supported by 40+ years of R&D in Rh incompatibility prevention with dedicated microsite at antid.com for educational resources.
• Tidilan Uterine muscle relaxant medication for preventing premature labor in expecting mothers. Brand acquired by BSV from Jagdale Industries in 2022.
• Hucog-HP (Human Chorionic Gonadotropin) Human-derived chorionic gonadotropin for fertility treatments and pregnancy support.
• Carbitex-HS Women's health medication addressing specific gynecological conditions.
• Ironject Iron supplementation product for treatment of iron deficiency and anemia in pregnancy.
• BSVwithU Knowledge Hub Digital engagement platform for healthcare professionals in women's health and fertility medicine providing access to journals, textbooks, continuous medical education modules, expert-led videos, webinars, and peer discussions.
• StartYourJoy BSVwithU patient support initiative providing interest-free loan services for IVF treatment in partnership with finance partners, along with tele-counselling support, accessible via startyourjoy.com microsite.

Quantifiable outcome

• Trinbelimab has significantly prevented hemolytic disease in newborns (HDN) by providing reliable supply in India for over 35 years
• +2 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature15 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• Quest GlobalminorGTM or Marketing Partner · 9 June 2026BSV joined Quest Global's 'Break the Silence' campaign to break silence around pregnancy loss in the workplace, partnering with mental health platform YourDOST to provide 24-hour helpline, peer-support groups, and manager training modules for working women in India.
• MediWoundcoreGTM or Marketing Partner · 24 February 2024BSV signed exclusive distribution agreement with MediWound (NASDAQ: MDWD) to introduce NexoBrid, a revolutionary enzymatic debridement treatment for severe burns that can treat patients in few hours.
• FOGSI (Federation of Obstetric and Gynaecological Societies of India)coreStrategic or Co-development Partner · 7 February 2024BSV and FOGSI collaborated through RISHTA 2024 initiative to increase breastfeeding and post-partum care awareness, including 'Train the Trainer' programme in six cities, and partnership for colposcopy awareness and access.
• Y4D (Youth for Development)minorOthers · 1 January 2024Digital transformation of 7 classrooms in 2 government schools in Jalna district, Maharashtra through Y4D X BSV partnership, helping 400+ students attain world-class education.
• Bureau Veritas India Pvt LtdminorImplementation/ SI/ Consulting Partner · 26 July 2023BSV engaged Bureau Veritas India as part of BSV ART Act Readiness Programme to assess ART centers against six critical parameters: infrastructure, people competency, communication, patient and process selection.
• Amp Energy IndiaminorOthers · 6 February 2023Amp Energy India commissioned a 5 MW solar power plant for BSV as an open-access solar project, supporting BSV's sustainability initiatives.
• National Chemical Laboratory (NCL)coreStrategic or Co-development Partner · 12 June 2022BSV forged industry-academia collaboration with NCL focusing on evaluation of certain recombinant cell line technologies developed by NCL for biopharmaceutical products under development.
• ISAR (Indian Society for Assisted Reproduction)coreStrategic or Co-development Partner · 1 January 2021BSV partnered with ISAR to provide IVF-ICSI treatment for poor patients through CSR expenditure, covering lab support, IVF culture media, consumables, and embryologist fees for 20 patients at member ART facilities.
• Abhinav Bindra FoundationminorStrategic or Co-development PartnerBSV partnered with Abhinav Bindra Foundation to create Sports4Her program - an inclusive ecosystem to empower and encourage female athletes through high-performance training, injury management, nutrition, mental wellness, mentorship, and leadership development.
• YourDOSTminorGTM or Marketing PartnerMental health platform partnered with BSV and Quest Global to provide 24-hour helpline, peer support circles, and HR training materials for pregnancy loss support.

Scale indicators13 records

Recent moves6 records

Expansion highlights1 record

Broad incumbents

• Serum Institute of India: World's largest vaccine manufacturer by doses, headquartered in Pune, India. Comparable to BSV in biological product manufacturing, Indian-origin biopharmaceuticals, and emergency medicine (anti-rabies, anti-snake venom) portfolios, though with much broader vaccine scope.
• Zydus Cadila (Zydus Lifesciences): Major Indian pharmaceutical company with significant biosimilars, vaccines, and specialty pharmaceuticals portfolio. Comparable manufacturing scale and regulatory infrastructure to BSV, with overlap in critical care and women's health therapeutic areas.
• Sun Pharmaceutical Industries: Largest Indian pharmaceutical company by revenue with global specialty/generics footprint. Competes with BSV in women's health (BSV's COO Sivani Sarma Deka came from Sun Pharma) and has broader chronic, acute, and specialty therapeutic reach.
• Cipla: Major Indian pharmaceutical manufacturer with significant respiratory, anti-retroviral, and critical care portfolios. Comparable manufacturing operations and India/global commercial reach; multiple BSV senior leaders previously worked at Cipla.
• Dr. Reddy's Laboratories: India-headquartered multinational pharmaceutical company with biologics, biosimilars, and specialty pharmaceuticals. Comparable in biosimilar development platform and Indian regulatory infrastructure, with much larger global generics footprint.
• Lupin: Major Indian pharmaceutical company with women's health, biosimilars, and complex generics. BSV's VP Medical Affairs previously led teams at Lupin, indicating direct talent overlap and likely therapeutic-area competition.

Direct peers

• Intas Pharmaceuticals: Indian biopharmaceutical company with direct overlap in women's health, fertility/IVF hormones, and biosimilars. Competes with BSV in rFSH/rHCG fertility segment and anti-rabies immunoglobulins, and recently hired BSV's former National Sales Manager for its Intas Women Healthcare business.
• Biocon: India's largest biopharmaceutical company focused on biosimilars, biologics, and novel biologics. Directly comparable in monoclonal antibody production, recombinant protein platforms, and biosimilar development pipeline, though more oncology-focused versus BSV's women's health focus.

Emerging players

• Wockhardt: Indian pharmaceutical and biotechnology company focused on biologics, biosimilars, and novel antibiotics. Comparable in biological products manufacturing and biosimilar pipeline; smaller than BSV but with stronger antibiotics portfolio.

Others

• Mankind Pharma: Parent company of BSV since October 2024 acquisition. Comparable in Indian pharmaceutical manufacturing, women's health, and fertility portfolio — though much larger scale with broader chronic, acute, and consumer health reach; serves as both owner and strategic channel for BSV products.

Market position

Strengths5 records

Competitive moat6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/BharatSerumsLtd

Compliance17 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bharat Serums and Vaccines